1 / 6

Emerging Treatment Protocols

Emerging Treatment Protocols. Eric Klein, MD. Phase III Chemoprevention Trials. RRR = 22.5%. RRR = 23.5%. PCPT. REDUCE. Prevention: What I Tell Patients. Low calorie diet Exercise Vitamin E and Selenium don’t work Data on other dietary changes and supplements not proven

darin
Télécharger la présentation

Emerging Treatment Protocols

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Emerging Treatment Protocols Eric Klein, MD

  2. Phase III Chemoprevention Trials RRR = 22.5% RRR = 23.5% PCPT REDUCE

  3. Prevention: What I Tell Patients • Low calorie diet • Exercise • Vitamin E and Selenium don’t work • Data on other dietary changes and supplements not proven • 5-alpha reductase inhibitors are safe and effective, and the only intervention supported by results of Phase III controlled trials

  4. 5ARIs for Biochemical Recurrence Andriole et al, Urology 45:491, 1995

  5. ARTS Study Design Multicenter, randomized, double-blind, placebo-controlled trial (n=276) End of treatment Randomization Treatment period 2 years Placebo Follow-up Screening Avodart (dutasteride) 0.5mg/day • 3 • weeks 15 21 6 12 18 3 9 0 +4 months 24 Months Baseline Negative bone scan PSA nadir

  6. ARTS Endpoints • Time to PSA doubling (primary) • Time to disease progression and percentage of patients with disease progression • Percentage of patients with treatment response (any PSA decrease or an increase 15%) • Changes in PSA including: • Time to PSA rise and percentage of patients with a PSA rise • Time to PSA progression and percentage of patients with PSA progression • Absolute and percentage PSA change from baseline and nadir PSA • Changes in PSA doubling time during treatment • Disease-related patient anxiety (MAX-PC) • Safety outcomes

More Related